Treatment proven to demonstrate significant survival improvement in patients with mCRC whose disease has progressed despite treatment with oxaliplatin-based regimen2 Sanofi and Regeneron Pharmaceuticals, Inc. announced today that they have launched ZALTRAP (aflibercept) which is licensed for use...
For patients with non-small cell lung cancer (NSCLC) the accurate determination of the lymph node status before therapy is critical to develop an individualized treatment plan. Research from the October issue of The Journal of Nuclear Medicine highlights a new way for this information to be...